U.S. Food & Drug Administration (2019) FDA Expands Indication for Several Transcatheter Heart Valves to Patients at Low Risk for Death or Major Complications Associated with Open-Heart Surgery.
https://www.fda.gov/news-events/press-announcements/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-or-major

has been cited by the following article:

• TITLE: Adaptation of Transcatheter Aortic Valve Replacement in Nursing

  AUTHORS: Nami B. Osterwald, Raymund Gantioque

  KEYWORDS: Transcatheter Aortic Valve Replacement, TAVR, Transcatheter Aortic Valve Implantation, TAVI, Aortic Stenosis

  JOURNAL NAME: Open Journal of Nursing, Vol.10 No.4, April 27, 2020

  ABSTRACT: Transcatheter aortic valve replacement (TAVR), which is also referred to as transcatheter aortic valve implantation (TAVI), is a minimally invasive procedure to treat aortic stenosis. An estimated 12% of individuals over the age of 75 have aortic stenosis, and it is currently the most common reason for valve replacement in elderly Americans. TAVR was introduced as an alternative treatment to surgical aortic valve replacement (SAVR), which involves an open-heart surgery. In the U.S., the first transcatheter valve was approved by the U.S. Food and Drug Administration (FDA) in November 2011. Since then, FDA has expanded its approval to intermediate- and low-risk patients. The purpose of this manuscript is to expand nurses’ knowledge about the TAVR procedure as TAVR is one of the most rapidly growing medical procedures in the U.S. This manuscript provides a background of the TAVR procedure, reviews relevant research, and highlights common complications. Compared to SAVR, TAVR has established its safety, efficacy, and cost-effectiveness as a treatment option for patients with severe aortic stenosis.